Renovion, Inc.
ARINA-1, a nebulized ascorbic acid therapy for preventing bronchiolitis obliterans syndrome in lung transplant patients
- Sector
- Biotech
- Headquarters
- Chapel Hill, NC
- Founded
- 2013
- Latest Form D
- $15M, Mar 2023
- Total capital
- $23.9M
- Federal grants
- $2.7M
- 2 awards · 2020–2021
- Rank in peer group#389 of 514
- Private capital raised
- $21.3M
- 5 Form D · last Mar 2023
- 43 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 14 pending · first 2022
- Rank in peer group#48 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 5th filing$15M
- Federal grantHealth and Human S · Phase II · Phase 2 Clinical Trial Evaluating a Novel Therapy in Patients who are Post-lung Transplant$871K
- Federal grantHealth and Human S · Phase II · Phase 2 Clinical Trial Evaluating a Novel Therapy in Patients who are Post-lung Transplant$1.8M
- Private capital raisedForm D · SEC · 4th filing$5M
- Private capital raisedForm D · SEC · 3rd filing$492K
- Private capital raisedForm D · SEC · 2nd filing$350K
- Private capital raisedForm D · SEC · 1st filing$467K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#48 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- DANIEL W. COPELANDResearcherExecutive Officer, DirectorLinked by $2.7M in grants as PI
- DEREK FREDERICK WINSTANLYDirectorNamed in SEC Form D filings
- JON W. CIVITARESEDirectorNamed in SEC Form D filings
- Joseph W. DavisDirectorNamed in SEC Form D filings
- RICHARD W. MATTINGLYDirectorNamed in SEC Form D filings
- R. FREDERICK MCCOY, JR.DirectorNamed in SEC Form D filings
Show all 8 people
- Robert Frederick RyanDirectorNamed in SEC Form D filings
- THOMAS U. BARTONDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 21- PendingAqueous Solution Comprising A Glutathione SaltUSPTOApplication 19299047
- GrantedTreatment Of Respiratory Tract Diseases And Infections With Ascorbic Acid CompositionsUSPTOUS 12,427,180
- PendingStable Ascorbic Acid Compositions And Methods Of Using The SameUSPTOApplication 19226989
Show all 21 patent records
- Aqueous Solution Comprising A Glutathione SaltDec 4, 2025 · Application 19299047Pending
- Treatment Of Respiratory Tract Diseases And Infections With Ascorbic Acid CompositionsSep 30, 2025 · US 12,427,180Granted
- Stable Ascorbic Acid Compositions And Methods Of Using The SameSep 25, 2025 · Application 19226989Pending
- Aqueous Solution Comprising A Glutathione SaltSep 23, 2025 · US 12,419,932Granted
- Stable Ascorbic Acid Compositions And Methods Of Using SameJul 8, 2025 · US 12,350,307Granted
- Aqueous Solution Comprising A Glutathione SaltSep 24, 2024 · US 12,097,238Granted
- Stable Ascorbic Acid Compositions And Methods Of Using SameFeb 6, 2024 · US 11,890,315Granted
- Treatment Of Respiratory Tract Diseases And Infections With Ascorbic Acid CompositionsMar 14, 2023 · US 11,602,555Granted
- Stable Ascorbic Acid Compositions And Methods Of Using The SameNov 15, 2022 · US 11,497,786Granted
- Aqueous Solution Comprising A Glutathione SaltApplication PCTUS2023010081Pending
- Methods For Reducing Symptoms In Subjects Suffering From Bronchiectasis And Other Pulmonary DiseasesApplication PCTUS2025026910Pending
- Compositions And Methods For Treatment Of Subjects Suffering From A SARS-COV-2 InfectionApplication 63389752Pending
- Aqueous Solution Comprising A Glutathione SaltApplication 63296405Pending
- Stable Ascorbic Acid Compositions And Methods Of Using The SameApplication PCTUS2018061686Pending
- Stable Ascorbic Acid Compositions And Methods Of Using The SameApplication 62684700Pending
- Treatment Of Respiratory Tract Diseases And Infections With Glutathione CompositionsApplication PCTUS2017062412Pending
- Stable Ascorbic Acid Compositions and Methods of Using the SameApplication 62588300Pending
- Treatment Of Respiratory Tract Diseases And Infections With Ascorbic Acid CompositionsApplication 62423721Pending
- Compositions And Methods For Treatment Of Subjects Suffering From A SARS-COV-2 InfectionApplication PCTUS2023070345Pending
- Glutathione Lysine Conjugate CompoundsApplication 62423702Pending
- Methods For Reducing Cough In Subjects Suffering From BronchiectasisApplication 63640839Pending
Related companies, and why
- Skylark BioSimilar federal contract value in Biotech · null in contracts
- Lexaria Bioscience Corp.Similar federal contract value in Biotech · null in contracts
- SciSparc Ltd.Similar federal contract value in Biotech · null in contracts
- Mestag TherapeuticsSimilar federal contract value in Biotech · null in contracts
- VASCULONICS INCSimilar federal contract value in Biotech · null in contracts
- PredxBio, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .